Health & Medical Archives | Be Korea-savvy

Archive by category Health & Medical

Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting

Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting

GERMANTOWN, Md., Nov. 16 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that data from the Company’s Phase 2 study of NSI-189 in patients with major depressive disorder will be presented at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting, which is being held [...]

Telix Pharmaceuticals Limited Lists on the Australian Securities Exchange

Telix Pharmaceuticals Limited Lists on the Australian Securities Exchange

MELBOURNE, Australia, Nov. 15 (Korea Bizwire) — Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has today listed on the Australian Securities Exchange (ASX) after raising $50 million in a fully underwritten Initial Public Offering [...]

RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares

RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 13 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases and cancer, today announced the closing of its previously announced underwritten public offering of [...]

RedHill Biopharma Reports 2017 Third Quarter Financial Results

RedHill Biopharma Reports 2017 Third Quarter Financial Results

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 13 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases and cancer, today reported its financial results for the quarter ended September 30, 2017. [...]

Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update

Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update

GERMANTOWN, Md., Nov. 13 (Korea Bizwire) — Neuralstem, Inc. (NASDAQ:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, reported its financial results for the three and nine month periods ended September 30, 2017.             “We continue to evaluate the full Phase 2 data set for NSI-189 [...]

Vetter Expands its Footprint in Asia Pacific Region

Vetter Expands its Footprint in Asia Pacific Region

Songdo and Ravensburg, Nov. 10 (Korea Bizwire) - Vetter, one of the global leaders in prefilled drug-delivery systems, today announced the official opening of a new branch office in South Korea. The new office in Songdo is located within the biologics cluster which is often referred to as a ‘sweet spot’ by the industry as it houses numerous prominent [...]

RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease

RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 9 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the last patient has been enrolled in the Phase [...]

Telix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering

Telix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering

MELBOURNE, Australia, Nov. 9 (Korea Bizwire) — Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised $50 million following the close of its fully underwritten Initial Public Offering (IPO). The IPO was strongly supported [...]

RedHill Biopharma Prices Public Offering of its American Depositary Shares

RedHill Biopharma Prices Public Offering of its American Depositary Shares

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 8 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases and cancer, today announced the pricing of its previously announced underwritten public offering for [...]

Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer

Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer

GERMANTOWN, Md., Nov. 8 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the appointment of David Recker, MD, FACR, FACP, as Chief Medical Officer. “Given his extensive experience in the biopharma industry, Dr. Recker brings to Neuralstem an expertise that will be critical to the [...]